Initial treatment regimen. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Patients baseline characteristics. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Overall survival. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Progression-free survival by treatment. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Maintenance regimen and adverse event management. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

BCC-specific survival. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A... by Cho-Hao Lee (4114723)

“…To compare the efficacy and safety of MCFG and triazoles in the prevention and treatment of IFIs, we conducted a meta-analysis and trial sequential analysis (TSA).…”

Fig 6 - by Eric Yung-Sheng Su (13015474)

Effects of chronic treatment with compound-326 on plasma glucose and insulin during an OGTT, and HOMA-IR in DIO mice. by Hiroaki Yashiro (2231686)

Effects of chronic treatment with compound-326 on BW, calorie intake, and fat mass in DIO mice. by Hiroaki Yashiro (2231686)

Effects of chronic treatment with compound-326 on PD markers and gene expression in WAT in DIO mice. by Hiroaki Yashiro (2231686)

Table_4_Clinical Features of 50 Patients With Primary Adrenal Lymphoma.DOCX by Yan Wang (15435)

“…<p>Background and Objective: Primary adrenal lymphoma is a rare, progressive, easily misdiagnosed adrenal tumor with a poor prognosis. …”

Table_1_Clinical Features of 50 Patients With Primary Adrenal Lymphoma.DOCX by Yan Wang (15435)

“…<p>Background and Objective: Primary adrenal lymphoma is a rare, progressive, easily misdiagnosed adrenal tumor with a poor prognosis. …”

Table_2_Clinical Features of 50 Patients With Primary Adrenal Lymphoma.DOCX by Yan Wang (15435)

“…<p>Background and Objective: Primary adrenal lymphoma is a rare, progressive, easily misdiagnosed adrenal tumor with a poor prognosis. …”

Effects of chronic treatment with compound-326 on BW, calorie intake, and blood PD markers in DIO mice. by Hiroaki Yashiro (2231686)

N50 of ARN127 mediates aggregation inhibition by actin- regulatory pathways. by Suzanne Angeli (253927)

In the absence of chloride, two-fold decrease in [Na⁺]_e shifted GLT-1a E_rev by −28 mV at both low and high glutamate concentrations. by Anatoli Y. Kabakov (729047)

“…Arrows show amplitudes and directions of E_rev shifts associated with decrease in [Na⁺]_e. <b>(D)</b> Average E_rev shifts at [Glu^-]_e geometric means of 37.5 and 600 μM are approximately equal when [Na⁺]_e was decreased from 102 to 51 mM. …”

Effect of corrections on connectivity maps. by Jan Willem Koten (17743224)

Fli-1 directly activates miR-17-92 promoter and contributes to miR-17 and miR-20a expression in NN10#5 cells. by Samer Kayali (133888)

“…Histogram shows the relative decreases of pri-miRNA-17-92 transcript and mature miRNA levels in treated versus untreated cells (means and standard deviations from 3 independent experiments) with significant (p<0.01) decreases indicated by asteriks. …”

Top 50 results of a commercial kinase screen using [γ³³]-ATP and human obscurin SH3-DH as substrates. by Daniel Koch (388049)

“…While MST2 addition resulted in strong and saturable phosphorylation, TBK1 led to much lower phosphorylation levels and CaMK4 addition led to an intermediate phosphorylation level exhibiting a biphasic behaviour with phosphorylation levels decreasing at higher substrate concentrations. …”